{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:22:03Z","timestamp":1792444923387,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41401-022-01011-4","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T03:03:31Z","timestamp":1666321411000},"page":"832-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of two methods for tumour-targeting peptide modification of liposomes"],"prefix":"10.1038","volume":"44","author":[{"given":"Shi-qi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"1011_CR1","first-page":"6449","volume":"49","author":"P Vaupel","year":"1989","unstructured":"Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449\u201365.","journal-title":"Cancer Res"},{"key":"1011_CR2","first-page":"4373","volume":"49","author":"IF Tannock","year":"1989","unstructured":"Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373\u201384.","journal-title":"Cancer Res"},{"key":"1011_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/mp200292c","volume":"8","author":"JW Wojtkowiak","year":"2011","unstructured":"Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011;8:2032\u20138.","journal-title":"Mol Pharm"},{"key":"1011_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.colsurfb.2011.10.039","volume":"99","author":"L Tian","year":"2012","unstructured":"Tian L, Bae YH. Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf B Biointerfaces. 2012;99:116\u201326.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1011_CR5","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1016\/j.biomaterials.2007.06.011","volume":"28","author":"A B\u00e9duneau","year":"2007","unstructured":"B\u00e9duneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials. 2007;28:4947\u201367.","journal-title":"Biomaterials"},{"key":"1011_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0169-409X(99)00062-9","volume":"41","author":"J Sudimack","year":"2000","unstructured":"Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147\u201362.","journal-title":"Adv Drug Deliv Rev"},{"key":"1011_CR7","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/1097-0142(19810501)47:9<2228::AID-CNCR2820470920>3.0.CO;2-D","volume":"47","author":"D Vugrin","year":"1981","unstructured":"Vugrin D, Whitmore WF Jr, Sogani PC, Bains M, Herr HW, Golbey RB. Combined chemotherapy and surgery in treatment of advanced germ-cell tumors. Cancer. 1981;47:2228\u201331.","journal-title":"Cancer"},{"key":"1011_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/1097-0142(197509)36:3<881::AID-CNCR2820360309>3.0.CO;2-B","volume":"36","author":"DC Tormey","year":"1975","unstructured":"Tormey DC. Combined chemotherapy and surgery in breast cancer: a review. Cancer. 1975;36:881\u201392.","journal-title":"Cancer"},{"key":"1011_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4254\/wjh.v2.i2.58","volume":"2","author":"Z Morise","year":"2010","unstructured":"Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, et al. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2:58\u201364.","journal-title":"World J Hepatol"},{"key":"1011_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14656566.3.6.755","volume":"3","author":"M Markman","year":"2002","unstructured":"Markman M, Mekhail TM. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3:755\u201366.","journal-title":"Expert Opin Pharmacother"},{"key":"1011_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (taxol). N. Engl J Med. 1995;332:1004\u201314.","journal-title":"N. Engl J Med"},{"key":"1011_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.2165\/00003495-199448050-00009","volume":"48","author":"CM Spencer","year":"1994","unstructured":"Spencer CM, Faulds D. Paclitaxel. Drugs. 1994;48:794\u2013847.","journal-title":"Drugs"},{"key":"1011_CR13","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s12274-019-2488-3","volume":"12","author":"LY Wang","year":"2019","unstructured":"Wang LY, Zhou BJ, Huang SQ, Qu MK, Lin Q, Gong T, et al. Novel fibronectin-targeted nanodisk drug delivery system displayed superior efficacy against prostate cancer compared with nanospheres. Nano Res. 2019;12:2451\u20139.","journal-title":"Nano Res"},{"key":"1011_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","volume":"338","author":"T Yang","year":"2007","unstructured":"Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338:317\u201326.","journal-title":"Int J Pharm"},{"key":"1011_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","volume":"163","author":"\u0160 Koudelka","year":"2012","unstructured":"Koudelka \u0160, Tur\u00e1nek J. Liposomal paclitaxel formulations. J Control Rel. 2012;163:322\u201334.","journal-title":"J Control Rel"},{"key":"1011_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molmed.2012.04.012","volume":"18","author":"E Koren","year":"2012","unstructured":"Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med. 2012;18:385\u201393.","journal-title":"Trends Mol Med"},{"key":"1011_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/wnan.4","volume":"1","author":"RL Juliano","year":"2009","unstructured":"Juliano RL, Alam R, Dixit V, Kang HM. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:324\u201335.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"1011_CR18","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1021\/nn4057269","volume":"8","author":"DM Copolovici","year":"2014","unstructured":"Copolovici DM, Langel K, Eriste E, Langel \u00dc. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8:1972\u201394.","journal-title":"ACS Nano"},{"key":"1011_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/bip.20989","volume":"90","author":"VP Torchilin","year":"2008","unstructured":"Torchilin VP. Cell-penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers. 2008;90:604\u201310.","journal-title":"Biopolymers"},{"key":"1011_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/B:PHAM.0000019289.61978.f5","volume":"21","author":"EL Snyder","year":"2004","unstructured":"Snyder EL, Dowdy SF. Cell-penetrating peptides in drug delivery. Pharm Res. 2004;21:389\u201393.","journal-title":"Pharm Res"},{"key":"1011_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1359-6446(03)02623-0","volume":"8","author":"VP Torchilin","year":"2003","unstructured":"Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today. 2003;8:259\u201366.","journal-title":"Drug Discov Today"},{"key":"1011_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.addr.2009.06.001","volume":"61","author":"SB Fonseca","year":"2009","unstructured":"Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61:953\u201364.","journal-title":"Adv Drug Deliv Rev"},{"key":"1011_CR23","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.1016\/j.biomaterials.2013.04.065","volume":"34","author":"G Mondal","year":"2013","unstructured":"Mondal G, Barui S, Chaudhuri A. The relationship between the cyclic-RGDfK ligand and \u03b1v\u03b23 integrin receptor. Biomaterials. 2013;34:6249\u201360.","journal-title":"Biomaterials"},{"key":"1011_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jconrel.2013.10.003","volume":"173","author":"Y Sakurai","year":"2014","unstructured":"Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, et al. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J Control Rel. 2014;173:110\u20138.","journal-title":"J Control Rel"},{"key":"1011_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2015.09.009","volume":"217","author":"KR Shi","year":"2015","unstructured":"Shi KR, Li JP, Cao ZL, Yang P, Qiu Y, Yang B, et al. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin \u03b1v\u03b23 for the treatment of melanoma. J Control Rel. 2015;217:138\u201350.","journal-title":"J Control Rel"},{"key":"1011_CR26","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.biomaterials.2013.12.018","volume":"35","author":"WT Song","year":"2014","unstructured":"Song WT, Tang ZH, Zhang DW, Zhang Y, Yu HY, Li MQ, et al. Anti-tumor efficacy of c (RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. Biomaterials. 2014;35:3005\u201314.","journal-title":"Biomaterials"},{"key":"1011_CR27","doi-asserted-by":"publisher","first-page":"13673","DOI":"10.1039\/C8NR03297A","volume":"10","author":"LY Wang","year":"2018","unstructured":"Wang LY, Qu MK, Huang SQ, Fu Y, Yang LQ, He SS, et al. A novel \u03b1-enolase-targeted drug delivery system for high efficacy prostate cancer therapy. Nanoscale. 2018;10:13673\u201383.","journal-title":"Nanoscale"},{"key":"1011_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/adfm.201303222","volume":"24","author":"TY Jiang","year":"2014","unstructured":"Jiang TY, Mo R, Bellotti A, Zhou JP, Gu Z. Gel\u2013liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv Funct Mater. 2014;24:2295\u2013304.","journal-title":"Adv Funct Mater"},{"key":"1011_CR29","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1021\/acsnano.8b03800","volume":"12","author":"TY Jiang","year":"2018","unstructured":"Jiang TY, Wang T, Li T, Ma YD, Shen SY, He BF, et al. Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma. ACS Nano. 2018;12:9693\u2013701.","journal-title":"ACS Nano"},{"key":"1011_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biomaterials.2016.09.001","volume":"108","author":"X Song","year":"2016","unstructured":"Song X, Wan ZY, Chen TJ, Fu Y, Jiang KJ, Yi XL, et al. Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment. Biomaterials. 2016;108:44\u201356.","journal-title":"Biomaterials"},{"key":"1011_CR31","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1016\/j.biomaterials.2014.04.037","volume":"35","author":"XM Zhang","year":"2014","unstructured":"Zhang XM, Zhang Q, Peng Q, Zhou J, Liao LF, Sun X, et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials. 2014;35:6130\u201341.","journal-title":"Biomaterials"},{"key":"1011_CR32","doi-asserted-by":"publisher","first-page":"7980","DOI":"10.1016\/j.biomaterials.2013.07.014","volume":"34","author":"QY Zhang","year":"2013","unstructured":"Zhang QY, Tang J, Fu L, Ran R, Liu YY, Yuan MQ, et al. A pH-responsive \u03b1-helical cell-penetrating peptide-mediated liposomal delivery system. Biomaterials. 2013;34:7980\u201393.","journal-title":"Biomaterials"},{"key":"1011_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jconrel.2007.05.011","volume":"120","author":"T Yang","year":"2007","unstructured":"Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Rel. 2007;120:169\u201377.","journal-title":"J Control Rel"},{"key":"1011_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","volume":"277","author":"MK Qu","year":"2018","unstructured":"Qu MK, Lin Q, He SS, Wang LY, Fu Y, Zhang ZR, et al. A brain targeting functionalized liposomes of the dopamine derivative N-3, 4-bis (pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease. J Control Rel. 2018;277:173\u201382.","journal-title":"J Control Rel"},{"key":"1011_CR35","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12274-021-3553-2","volume":"15","author":"SQ Huang","year":"2018","unstructured":"Huang SQ, Deng L, Zhang HM, Wang LY, Zhang YC, Lin Q, et al. Co-delivery of TRAIL and paclitaxel by fibronectin-targeting liposomal nanodisk for effective lung melanoma metastasis treatment. Nano Res. 2022;15:728\u201337.","journal-title":"Nano Res"},{"key":"1011_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/sj.gt.3302910","volume":"14","author":"IA Khalil","year":"2007","unstructured":"Khalil IA, Kogure K, Futaki S, Hama S, Akita H, Ueno M, et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther. 2007;14:682.","journal-title":"Gene Ther"},{"key":"1011_CR37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/nn102722z","volume":"5","author":"B Jang","year":"2011","unstructured":"Jang B, Park JY, Tung CH, Kim IH, Choi Y. Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic\/photothermal therapy in vivo. ACS Nano. 2011;5:1086\u201394.","journal-title":"ACS Nano"},{"key":"1011_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","volume":"161","author":"T Lammers","year":"2012","unstructured":"Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Rel. 2012;161:175\u201387.","journal-title":"J Control Rel"},{"key":"1011_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1021\/nn402669w","volume":"8","author":"P Bigini","year":"2014","unstructured":"Bigini P, Previdi S, Casarin E, Silvestri D, Violatto MB, Facchin S, et al. In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. ACS Nano. 2014;8:175\u201387.","journal-title":"ACS Nano"},{"key":"1011_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.actbio.2015.05.021","volume":"23","author":"YJ Gao","year":"2015","unstructured":"Gao YJ, Zhou YX, Zhao L, Zhang C, Li YS, Li JW, et al. Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles. Acta Biomater. 2015;23:127\u201335.","journal-title":"Acta Biomater"},{"key":"1011_CR41","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1021\/nn305860k","volume":"7","author":"KT Al-Jamal","year":"2013","unstructured":"Al-Jamal KT, Al-Jamal WT, Wang JT, Rubio N, Buddle J, Gathercole D, et al. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. ACS Nano. 2013;7:1905\u201317.","journal-title":"ACS Nano"},{"key":"1011_CR42","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1021\/nn500216y","volume":"8","author":"ZH Xu","year":"2014","unstructured":"Xu ZH, Wang YH, Zhang L, Huang L. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano. 2014;8:3636\u201345.","journal-title":"ACS Nano"},{"key":"1011_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2020.03.049","volume":"325","author":"SQ Huang","year":"2020","unstructured":"Huang SQ, Zhang YC, Wang LY, Liu W, Xiao LY, Lin Q, et al. Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier. J Control Rel. 2020;325:10\u201324.","journal-title":"J Control Rel"},{"key":"1011_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nnano.2012.237","volume":"8","author":"A Salvati","year":"2013","unstructured":"Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8:137\u201343.","journal-title":"Nat Nanotechnol"},{"key":"1011_CR45","first-page":"29","volume":"9","author":"CB Spinks","year":"2017","unstructured":"Spinks CB, Zidan AS, Khan MA, Habib MJ, Faustino PJ. Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations. Clin Pharmacol. 2017;9:29.","journal-title":"Clin Pharmacol"},{"key":"1011_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2014.05.042","volume":"188","author":"AL Lain\u00e9","year":"2014","unstructured":"Lain\u00e9 AL, Gravier J, Henry M, Sancey L, B\u00e9jaud J, Pancani E, et al. Conventional versus stealth lipid nanoparticles: Formulation and in vivo fate prediction through FRET monitoring. J Control Rel. 2014;188:1\u20138.","journal-title":"J Control Rel"},{"key":"1011_CR47","doi-asserted-by":"publisher","first-page":"10071","DOI":"10.1039\/C5NR02247A","volume":"7","author":"D Xiao","year":"2015","unstructured":"Xiao D, Jia HZ, Ma N, Zhuo RX, Zhang XZ. A redox-responsive mesoporous silica nanoparticle capped with amphiphilic peptides by self-assembly for cancer-targeting drug delivery. Nanoscale. 2015;7:10071\u20137.","journal-title":"Nanoscale"},{"key":"1011_CR48","doi-asserted-by":"publisher","first-page":"9979","DOI":"10.1021\/ja981654z","volume":"120","author":"YC Yu","year":"1998","unstructured":"Yu YC, Tirrell M, Fields GB. Minimal lipidation stabilizes protein-like molecular architecture. J Am Chem Soc. 1998;120:9979\u201387.","journal-title":"J Am Chem Soc"},{"key":"1011_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/1097-0282(200012)54:7<531::AID-BIP60>3.0.CO;2-X","volume":"54","author":"P Forns","year":"2000","unstructured":"Forns P, Lauer\u2010Fields JL, Gao S, Fields GB. Induction of protein-like molecular architecture by monoalkyl hydrocarbon chains. Biopolymers. 2000;54:531\u201346.","journal-title":"Biopolymers"},{"key":"1011_CR50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bcp.2013.05.012","volume":"86","author":"J Han","year":"2013","unstructured":"Han J, Huang X, Sun LD, Li Z, Qian H, Huang WL. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. Biochem Pharmacol. 2013;86:297\u2013308.","journal-title":"Biochem Pharmacol"},{"key":"1011_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/op7002198","volume":"12","author":"HY Zhang","year":"2008","unstructured":"Zhang HY, Schneider SE, Bray BL, Friedrich PE, Tvermoes NA, Mader CJ, et al. Process development of TRI-999, a fatty-acid-modified HIV fusion inhibitory peptide. Org Process Res Dev. 2008;12:101\u201310.","journal-title":"Org Process Res Dev"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01011-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01011-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01011-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T04:14:36Z","timestamp":1679890476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01011-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-01011-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}